preamble_21
Whereas it is also necessary to make provisions for the supervision of medicinal products which have been authorized by the Community, and in particular for the intensive monitoring of adverse reactions to those medicinal products through Community pharmacovigilance activities in order to ensure the rapid withdrawal from the market of any medicinal product which presents an unacceptable level of risk under normal conditions of use;
← preamble_20 · All articles · preamble_22 →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.